A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2018
At a glance
- Drugs OBI 888 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors OBI Pharma
- 19 Jun 2018 Status changed from planning to recruiting.
- 18 Jan 2018 New trial record
- 17 Jan 2018 According to the OBI Pharma media release, company announced that U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application for a Phase 1 study of OBI-888.